Form 4: Bausch Health CEO Awarded 815K RSUs

Bausch Health Companies Inc. CEO Thomas Appio received an award of 815,425 restricted share units, with a portion subsequently withheld for tax obligations.

Summary

• CEO Thomas Appio was awarded 815,425 restricted share units (RSUs) on February 25, 2026, at a price of $0.
• These RSUs will vest one-third on each of the first three anniversaries following the grant date, contingent on continued service.
• On February 26, 2026, 116,502 common shares were disposed of at $6.04 per share to cover tax withholding obligations related to the vesting of Restricted Share Units.
• Following these transactions, Thomas Appio beneficially owns 3,620,034 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting continued executive alignment with shareholder interests through equity awards, which is a standard compensation practice.

Positives

• CEO Thomas Appio was awarded 815,425 restricted share units, aligning his interests with long-term shareholder value.
• The award of RSUs at a $0 price indicates a compensation component tied to future performance and retention.

Negatives

• 116,502 common shares were disposed of to satisfy tax withholding obligations, representing a reduction in direct share ownership.

Future Outlook

The RSUs will vest over three years, indicating a long-term retention strategy for the CEO and aligning his incentives with the company's sustained performance.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity awards like RSUs, is a common practice in the pharmaceutical and healthcare industry to align executive incentives with long-term company performance and shareholder interests. This type of award is standard for retaining key leadership.

Comparison to Industry Standards

• The grant of RSUs as a significant component of executive compensation is a standard practice across major pharmaceutical and healthcare companies, such as Pfizer, Johnson & Johnson, and Merck, which frequently use similar long-term incentive plans to retain and motivate top executives.
• The vesting schedule of one-third annually over three years is a common structure for RSU awards, comparable to plans observed at companies like AbbVie and Bristol Myers Squibb, designed to ensure executive commitment over a multi-year horizon.
• The disposition of shares to cover tax obligations upon RSU vesting is a routine and expected event for equity compensation, consistent with practices seen at virtually all publicly traded companies that grant equity awards.

Related Party Transactions

• The award of restricted share units to CEO Thomas Appio is a related party transaction, representing a component of his executive compensation.

Stakeholder Impact

• Shareholders: The RSU award aligns the CEO's long-term interests with shareholder value creation, potentially fostering sustained performance.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.

Next Steps

• One-third of the awarded RSUs will vest on the first, second, and third anniversaries following the grant date of February 25, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of RSU awards and subsequent tax-related share dispositions. While the RSU award aligns the CEO's interests with long-term shareholder value, it does not present new fundamental information that would significantly alter the company's valuation or immediate investment thesis. It is a standard, expected event in executive compensation, thus warranting a 'hold' recommendation as it neither strongly supports a buy nor a sell decision based solely on this filing.

Keywords

Bausch Health Companies Inc., BHC, Thomas Appio, Restricted Share Units, RSUs, Insider Ownership, Executive Compensation, SEC Form 4, Stock Award, Tax Withholding